Company Profile for Multicell Technologies, Inc.MultiCell Technologies, Inc., (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :MUCL MUCL Mount Union College Library (Alliance, OH) ) provides non-tumorigenic functional hepatic (liver) cells and cell lines to pharmaceutical companies for induction studies and toxicity screening for drug discovery. Hepatocytes express drug-metabolizing enzymes, which bio-transform drugs or substances ingested into the body. Drug failures or FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. rejections due to hepatotoxicity hepatotoxicity (hepˑ·  ·tō·t and/or drug-drug interactions
now cost the pharmaceutical industry an estimated $2 billion each year.
It costs about $900 million to develop and test a new medicine.
XenoTech, LLC of Lenexa, KS is the exclusive marketing and manufacturing
licensee for MultiCell's proprietary immortalized hepatocyte hepatocyte /hep·a·to·cyte/ (hep´ah-to-sit?) a hepatic cell. hep·a·to·cyte n. A parenchymal liver cell. Hepatocyte A liver cell. cell lines. MultiCell's cellular product expertise also enables production of biologics for use in diagnostic and therapeutic applications, as well as production of liver-derived therapeutic proteins. The Company's majority-owned Xenogenics subsidiary owns all rights to the patented Sybiol(TM) synthetic bio-liver device. MultiCell's immortalized hepatocytes are hoped to operate optimally with any working bio-liver device and thus facilitate serving as a bridge for patients, waiting for liver transplants and as a treatment option for chronic liver disease Chronic liver disease is a liver disease of slow process and persisting over a long period of time, resulting in a progressive destruction of the liver. It includes amongst others:
The company's Scientific Advisory Board (SAB) is headed by Dr. Ronald Faris, Ph.D., Senior Vice President, Chief Science Officer and SAB Chairman. The SAB includes noted scientists Sangeeta Bhatia, M.D., Ph.D.; Douglas Hixson, Ph.D.; Edward Maggio, Ph.D.; Andrew Parkinson, Ph.D.; Stephen Chang, Ph.D.; and Dr. Richard Ulevitch , Ph.D..
Company: MultiCell Technologies, Inc.
Headquarters Address: 55 Access Road
Suite 700
Warwick, Rhode Island 02886
Main Telephone: 401-738-7560
Website: www.multicelltechnologies.com
Ticker: MUCL(OTCBB)
Type of Organization: Public
Industry: Health: Biotechnology
Earnings Release Dates: 3rd Quarter: October 15, 2004
4th Quarter: January 15, 2004
Key Executives: CEO: Jerry Newmin
VP, CSO: Ronald Faris
Investor Relations
Contact: Barbara Corbett
Email: MUCLinvestor@aol.com
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion